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Bone scaffolds loaded with siRNA-
Semaphorin4d for the treatment of 
osteoporosis related bone defects
Yufeng Zhang1,2, Lingfei Wei1, Richard J. Miron1,3,4,  Bin Shi1,2 & Zhuan Bian1
Osteoporosis is a prominent disorder affecting over 200 million people worldwide. Recently, 
semaphorins have been implicated in the cell-cell communication between osteoclasts and osteoblasts 
and have been associated with the progression of osteoporosis. Previously, we demonstrated that 
knockdown of semaphorin4d (Sema4d) using siRNA delivered with a bone-targeting system prevented 
bone loss in an osteoporotic animal model. Here, we used this bone-specific technology containing 
siRNA-Sema4d and fabricated a PLLA scaffold capable of enhancing bone repair following fracture. We 
investigated the ability of the implant to release siRNA-Sema4d into the surrounding tissues over time 
and to influence new bone formation in a 3 mm femur osteoporotic defect model in ovariectomized rats. 
Delivery of the bone-targeting system released from PLLA scaffolds began 2 hours post-implantation, 
peaked at 1 day, and was sustained over a 21 day period. μCT analysis demonstrated a significantly 
higher bone volume/total volume bone mineral density and number of osteoblasts in the rats that 
were transplanted with scaffolds loaded with siRNA-Sema4d. These results confirm the specific role of 
Sema4d in bone remodeling and demonstrate that significant increases in the speed and quality of new 
bone formation occur when siRNA-Sema4d is delivered via a PLLA scaffold.
Osteoporosis is a global healthcare issue with an increasing socio-economic burden. It is caused by an imbalance 
between bone-forming osteoblasts and bone-resorbing osteoclasts1,2. Over 200 million people are affected world-
wide3, with the majority of patients being white or Asian women over 65 years old4. For decades, research has 
shown that osteoporotic patients demonstrate reduced healing after bone injury5. Fractures are more common, 
and their healing potential is drastically reduced5. The disease is caused by hyper-activity of osteoclasts, which 
affects the bone remodeling cycle and limits the ability of the incoming bone-forming osteoblasts to lay new bone 
matrix2,6–10.
At present, the two major pharmacological approaches for the treatment of osteoporosis are as follows: stim-
ulation of bone formation via anabolic agents (such as parathyroid hormone) or prevention of bone resorp-
tion via anti-resorptives (such as bisphosphonates, calcitonin, raloxifene, and estrogen replacement therapy)11. 
Semaphorins have recently been targeted as molecules with osteoporosis treatment potential. They are directly 
implicated in the cell-cell communication between osteoclasts and osteoblasts and may be a novel target for the 
treatment of osteoporosis12–21. Furthermore, the overexpression of semaphorin4d (Sema4d) in bone tissues has 
been associated with osteoporosis in an animal model22. A Sema4d knockout animal model recently demon-
strated an increase in bone thickness and density, further implicating Sema4d in the bone remodeling cycle.
Previously, we have developed a site-specific bone-targeting drug delivery system consisting of polymeric 
nanoparticles containing an siRNA-mediated gene knockdown system for Sema4d23. This system specifically 
targets native bone and releases siRNA-Sema4d onto bone surfaces occupied by osteoclasts. Weekly injections of 
this system significantly improved bone formation in both an early and late phase osteoporotic animal model by 
re-balancing the bone remodeling cycle23.
While most of the current osteoporosis research focuses on fracture prevention using a variety of pharma-
cological agents, the treatment of osteoporosis-related defects following fracture has not been as well studied. 
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Therefore, in this study, we fabricated a specific bone replacement material from poly-L-lactic acid (PLLA) scaf-
folds to promote bone formation in an osteoporotic phenotype and studied this in 3 mm femur defects in ovariec-
tomized (OVX) rats. The PLLA scaffolds were then loaded with a bone-specific targeting system that contained 
siRNA-Sema4d to improve bone remodeling, and new bone formation was investigated.
Materials and Methods
Preparation and characterization of PLLA. Four groups were used for all animal experiments: 1) drilled 
control, 2) PLLA alone, 3) PLLA-(Asp8-(STR-R8)) and 4) PLLA-(Asp8-(STR-R8)-siRNA-Sema4d. Porous PLLA 
scaffolds were prepared using a previously described freeze-drying method24. Briefly, 1g PLLA (Sigma #765112; 
Sigma-Aldrich, St. Louis, USA) was dispersed in 10 ml dioxane (Sinopharm Chemical Reagent Co., Ltd, Shanghai, 
China) under vigorous stirring until completely dissolved. Then, the mixture was rapidly transferred to a freezer 
at − 35 °C overnight to solidify the solvent and induce solid–liquid phase separation. This solidified mixture 
was then maintained at − 80 °C for 2 h and subsequently transferred into a freeze-drying vessel (Christ Beta 
1–15, Germany) for 48 h until dried. Scaffolds were then sterilized and lyophilized. The Asp8-(STR-R8)-siRNA-
Sema4d (covalently linked) bone targeting system was fabricated as previously described23. Briefly, the packaging 
of siRNA (GenePharma, Suzhou, China) was performed according to a protocol adapted from DNA transfec-
tion experiments25. Asp8-Stearyl-R8 (1.5 μ l) (ChinaPeptides Co., Ltd, Shanghai, China) was diluted in 50 μ l of 
unsupplemented Neurobasal medium (Gibco® , USA) and combined with 10 pmol of siRNA in 50 μ L of unsup-
plemented Neurobasal medium. The solution was incubated for 5 min at room temperature. The PLLA (0.01 g) 
was then incubated with 1 ml of Asp8-(STR-R8)-siRNA-Sema4d solution or Asp8-(STR-R8) solution (5 OD/ml) 
at 4 °C overnight to allow complete infiltration. These complexes were then frozen by immersion at − 80 °C for 2 h 
and subsequently lyophilized.
Animals and surgical procedures. Mature female Wistar rats (12 weeks old, mean body weight 250 g) 
were purchased and used for this study. All handling and surgical procedures were approved by the Ethics 
Committee for Animal Research, Wuhan University, China. The methods were carried out in “accordance” with 
the approved guidelines. Animals received food and water ad libitum and were housed at a constant temperature 
of 22 °C. For surgery, the animals were place under general anesthesia using an intraperitoneal injection of chloral 
hydrate (Sinopharm Chemical Reagent Co., Ltd, Shanghai, China, 10%, 4 ml/kg body weight), and all operations 
were performed under sterile conditions with a minimally invasive surgical technique. Postoperatively, penicillin 
Figure 1. The kinetics of Asp8-(STR-R8) release/distribution in femurs over 21 days. The epi-fluorescence 
indicated sustained and localized drug distribution restricted to the defect and the adjacent bone tissue and 
peaking at 1 day post-implantation.
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(40,000 IU/ml, 1 ml/kg) was injected each day for 3 days. There were no signs of inflammation or other notable 
anomalies.
Osteoporosis model. The animals were acclimatized to the new laboratory surroundings for one week. The 
osteoporotic animal model was established using a bilateral ovariectomy (OVX)26. Briefly, under general anesthe-
sia, the rats received 10 mm linear incisions bilaterally in the lumbar skin. Both ovaries were gently removed. The 
tissue layers were then repositioned and sutured. Following surgery, buprenorphine (0.05 mg/kg) was adminis-
tered by subcutaneous injection for pain management.
Femoral defect model. Standardized 3 mm femoral cylindrical defects were created in ovariectomized ani-
mals 2 months after the bilateral removal of the ovaries. The osteoporosis model should have been established at 
this time point according to previous studies27,28. A distal femoral epiphysis linear skin incision (approximately 
1 cm) was performed bilaterally. The femoral condyles were then exposed by blunt dissection of the muscles sur-
rounding the femurs. A 2.8 mm diameter reamer was used to create a 3.0 mm diameter anteroposterior bicortical 
channel perpendicular to the shaft axis (Supplemental Fig. 1A (reprint with permission from Cheng et al.27)). 
The bur was irrigated at a slow speed (800 rpm) and rinsed with saline solution to avoid thermal necrosis of the 
cells and tissues. The bone fragments were washed out of the cavity using the saline solution. Scaffolds (3 mm in 
diameter by 5 mm in thickness) were gently placed bilaterally according to a randomized group allocation. The 
incisions were then closed. Buprenorphine (0.05 mg/kg) was administered by subcutaneous injection for postop-
erative pain management.
Pharmacokinetics study. PLLA scaffolds were cut using custom trays (3 mm in diameter and 5 mm in 
thickness), gently loaded with rhodamine-labeled Asp8-(STR-R8) and placed within the femurs. Samples were 
collected at 0 hours, 12 hours, 1 day, 3 days, 7 days, 14 days and 21 days post-operation to assess the duration 
and location of drug distribution. The fluorescence signal was detected using a Xenogen IVIS imaging system 
(Xenogen, Alameda, Ca, USA) as previously described23.
Bone regeneration. To study bone regeneration in the osteoporotic femoral defect, the rats were divided 
into four groups: 1) drilled control, 2) filled with PLLA, 3) filled with PLLA-(Asp8-(STR-R8)) and 4) filled with 
PLLA-(Asp8-(STR-R8)-siRNA-Sema4d) (n = 15 in all groups). Rats were sacrificed at 2, 4 and 8 weeks after fem-
oral surgery. The defect, size, shape and location are presented in supplemental Fig. 1. The rats were divided into 
four groups with 6 defects per group per time point.
Micro-CT (μCT) analysis of osteogenesis in the femoral defect. After harvesting at each time point, 
the femurs were removed intact and fixed in 4% freshly prepared formaldehyde for 24 h at 4 °C. The μ CT imag-
ing system (μ CT50, Scanco Medical, Brüttisellen, Switzerland) was used to evaluate the osteogenesis within the 
Figure 2. Representative images of overall bone regeneration using 3D reconstruction at 8 weeks post-
implantation. The siRNA-Sema4d treated group had significantly increased mineralization in trabecular 
bone compared to the control, PLLA alone and PLLA-(Asp8-(STR-R8)-siRNA-Sema4d loaded defects. The 
bottom row represents the 3-dimensional reconstruction of the bone defects from the micro-CT analysis, 
demonstrating higher bone density for the group treated with siRNA-Sema4d.
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defect region. The study parameters used were previously reported26,29–31. The scanning parameters, reconstructed 
parameters and analysis parameters were entered into the μ CT scanner. A consistent volume of interest (VOI) 
was located in the central 2.5-mm-diameter region of the 3-mm-diameter defect. The middle third (by length) 
was used to evaluate the level of bone regeneration. Mineralized bone tissue was differentially segmented with a 
fixed low threshold (value = 184). The bone volume fractions (BV/TV), trabecular thickness (Tb.Th) and tissue 
mineral density were automatically collected and analyzed using the μ CT software as previously described26,29–31. 
Representative sections were taken from the vertical view, and a representative cube of VOI was acquired by 3D 
reconstruction.
Histological observation and analysis. Following μ CT scanning, femurs were removed and decalcified 
in 10% EDTA. The solution was changed twice weekly for 3 weeks. The samples were embedded in paraffin 
with the long axis parallel to the base plane. Serial sections (5 μ m) were cut and mounted on polylysine-coated 
slides. The samples were analyzed using H&E staining and tartrate-resistant acid phosphatase (TRAP) staining 
(Sigma #387A; Sigma-Aldrich, St. Louis, USA) in accordance with the manufacturer’s protocol. The expression of 
SEMA4D and osteocalcin (BGLAP) were detected according to the following immunohistochemical procedure. 
The samples were deparaffinized, rehydrated and washed. The sections were then processed for antigen retrieval 
by using trypsin and then incubated with 0.3% hydrogen peroxide for 20 min followed by incubation with nor-
mal goat serum. The sections were incubated with a primary antibody specific for SEMA4D (1:250; 14422-1-AP, 
Figure 3. Statistical analysis of bone volume/total volume (BV/TV), trabecular thickness and tissue 
mineral density in the bone defect as assessed by μCT. All data are shown as the mean ± SD. P < 0.05.  
*Compared to drilled blank control; **significantly higher than all other groups.
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Figure 4. Representative sections with H&E staining for all treatment groups. 
Figure 5. Representative sections stained for Sema4d-positive cells revealed the success of the sustained 
knockdown of Sema4d. A significant reduction in the number of Sema4d positive cells in the PLLA-(Asp8-
(STR-R8)-siRNA-Sema4d) filled group was observed at 2 and 4 weeks post-implantation compared to the 
other groups. By 8 weeks post-implantation, no differences were observed between the groups that received the 
scaffolds. Control unfilled scaffolds had significantly more Sema4d-positive cells than all other groups. All data 
are shown as the mean ± SD. P < 0.05. *Compared to drilled blank control; **significantly higher than all other 
groups.
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Proteintech. Inc., US) or BGLAP (1:200; BA1677-1, Boster, China) for 2 h at 37 °C. The sections were then incu-
bated using the SP 9000 immunohistochemical kit (Zhongshan Biotechnology Co., Ltd, China) and visualized 
with 3, 3-diaminobenzidine tetrahydrochloride (DAB) (Zhongshan Biotechnology Co., Ltd, China). The sections 
were counterstained with hematoxylin. TRAP-positive osteoclasts were stained red and were identified by the 
presence of three or more nuclei. Each defect was assayed in triplicate for each of the 6 animals per group at the 3 
time points (54 samples per group).
Statistical analysis. Statistical analyses were performed using a one-way ANOVA and the Student- 
Newman-Keuls test. Results were considered statistically significant at p < 0.05. All data are expressed as the 
mean ± standard deviation (SD).
Results
Sustained and localized release in vivo. Images of a representative femur filled with PLLA scaffold 
incorporating rhodamine-labeled Asp8-(STR-R8) depict the kinetics of the sustained and localized drug distri-
bution for a period of 21 days (Fig. 1). The release of (measurable) Asp8-(STR-R8) was used as a surrogate marker 
for the release of siRNA-Sema4d. The rhodamine-labeled Asp8-(STR-R8) was released from PLLA scaffolds over 
time but restricted to the defect and adjacent bone tissue. The highest labeling was observed at 1 day post-implan-
tation of the scaffold, and labeling was maintained (albeit in low quantities) for 21 days (Fig. 1).
μCT analysis of osteogenesis in the femoral defect. Representative images of bone regeneration in the 
femoral defect, performed by 3D reconstruction for each group, are shown in Fig. 2. A minimal amount of new 
bone formation was found in the unfilled defects at all time points (Fig. 2). The three defects filled with scaffolds 
demonstrated improved bone formation and mineralization compared to the unfilled defects. The siRNA-Sema4d 
treated group regenerated the highest amounts of mineralized bone (Fig. 2). Quantitative analyses demonstrated 
that the bone volume, trabecular thickness and tissue mineral density of the siRNA-Sema4d treated group were 
significantly higher than those of the PLLA filled group at 8 weeks post-operation (Fig. 3). The unfilled group had 
the lowest values of all treatment groups at 4 and 8 weeks post-operation (Fig. 3).
Figure 6. Representative images of BGLAP immunohistochemical staining revealed osteoblast-related 
bone regeneration in the filled bone defect. The statistical analysis indicated increased numbers of activated 
osteoblasts at 4 weeks post-operation in the PLLA-(Asp8-(STR-R8)-siRNA-Sema4d) filled group than with all 
other modalities. All data are shown as the mean ± SD. P < 0.05. *compared to drilled blank control;  
**compared to all other groups.
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Histological and immunohistochemical analysis. Representative images of H&E staining of the fem-
oral defect are shown in Fig. 4. At 2 weeks post-implantation, bone regeneration was observed at the periphery 
of the defect sites in all groups in which the defects were filled with scaffolds. There were no significant differ-
ences between groups and only a small amount of new bone regeneration had occurred (Fig. 4). At 4 weeks 
post-implantation, the unfilled group demonstrated little to no new bone formation. Bone formation had not 
improved further at 8 weeks post-surgery (Fig. 4). The scaffold groups had a significantly larger bone area than 
did the controls at both 4 and 8 weeks (Fig. 4). The scaffolds that were pre-loaded with siRNA-Sema4d further 
supported new bone formation compared to all other treatment modalities at 4 and 8 weeks.
Quantitative analysis was used to determine the number of Sema4d-stained cells (Fig. 5), the number of oste-
oblasts (Fig. 6) and the number of osteoclasts (Fig. 7). Staining of Sema4d positive cells demonstrated a 3-fold 
decrease in such cells at 2, 4 and 8 weeks in scaffolds that contained siRNA-Sema4d. This result confirmed the 
functioning of the in vivo knockdown system (Fig. 5). The number of osteoblasts was counted in the histological 
sections, which were also stained with BGLAP (Fig. 6). No difference in osteoblast number was observed at 2 
weeks between all groups implanted with scaffolds. However, the scaffolds with siRNA-Sema4d led to significantly 
higher number of osteoblasts at 4 weeks than did the control scaffolds and returned to baseline PLLA control val-
ues by 8 weeks (Fig. 6). TRAP-positive osteoclasts were observed in all four groups around newly formed bone, 
with no differences among the three implanted scaffold groups (Fig. 7).
Discussion
Recently, semaphorins have been targeted as molecules that are directly implicated in the cell-cell cross-talk 
between osteoclasts and osteoblasts12–21. They were originally identified as axon-guidance molecules but have 
since also been demonstrated to have important roles outside the nervous system. They play key roles in cell 
migration, cell-cell communication, tissue development and angiogenesis32–37. Their specific targeted delivery is 
important because of their widespread activity in the nervous system and other tissues. We previously developed 
a site specific targeting system with D-Asp823. When intravenously injected into rats (over 4 weeks), we were able 
to locate and target bone with little to no delivery to surrounding tissues23. In the present study, we developed 
a scaffold carrying siRNA-Sema4d and investigated its release into bone tissues over time. In the past few years, 
siRNA has been investigated for the treatment of various diseases because of its ability to silence various genes 
responsible for pathology38–41. At 1 day post-implantation, the release of the vector had peaked and then gradu-
ally decreased over time (Fig. 1). The bone targeting system was expressed in the shaft of the femur. The delivery 
of this targeting system to bony tissues near the fracture site is a desirable feature because the development of 
osteoporosis leads to a reduction in bone specifically in the trabecular regions. The delivery system has previously 
Figure 7. Representative sections revealed the bone remodeling process by TRAP positive osteoclasts 
during the pre-arranged observation period at 2, 4 and 8 weeks post-implantation. The statistical analysis 
indicated no difference in TRAP staining between the three filled defects at any of the tested time points. All 
data are shown as the mean ± SD. P < 0.05. *compared to drilled blank control).
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been shown to target native bone undergoing bone remodeling. In the present study, we demonstrated that local 
implantation of this system into tissues with low bone density (an osteoporotic animal model) may improve 
the regeneration of bone following fracture/bone defects. Therefore, local implantation of a scaffold system that 
is both a bone replacement material and an osteopromotive agent may result in improved fracture healing in 
patients.
It has previously been reported from studies of knockout animals that the role of Sema4d in osteoclast activity 
is mediated by its receptor, Plexin-B1, which is expressed by osteoblasts16,42. There is now increasing evidence 
from pre-clinical studies that Sema4d is expressed at a higher level in osteoporotic animals22. Therefore, Sema4d 
is an important and viable target for gene silencing. In our previous study, we demonstrated that the knockdown 
of Sema4d in osteoclasts, which were co-cultured with bone marrow stromal cells, led to an increase in alkaline 
phosphatase activity. It also increased the mineralization potential and the upregulation of the genes encoding col-
lagen 1 and osteocalcin as assessed by real-time PCR23. The present study further supports these results by demon-
strating that the local implantation of this scaffold system increased tissue mineral density and BV/TV (Figs 2–4). 
The staining of Sema4d-positive cells was significantly decreased (over 3-fold) compared to blank or scaffold 
controls (Fig. 5). The scaffold system had little to no effect on the number of osteoclasts following transfection with 
siRNA-Sema4d and thereby did not halt the bone remodeling cycle (commonly reported during bisphosphonate 
use). One limitation of this study is that it does not focus on the activity of osteoclasts. Further research is needed 
to determine the potential effects of this system on the resorption properties of osteoclasts in vitro.
Conclusions
The PLLA scaffold containing siRNA-Sema4d improved new bone formation in an osteoporotic animal model. 
The knockdown of Sema4d in osteoclasts did not affect the number of osteoclasts on the bone surface. However, 
the number of osteoblasts significantly increased, suggesting that Sema4d has a role in the cross-talk between 
osteoclasts and osteoblasts. The field of biomaterials faces many challenges in meeting the globally increas-
ing demand for the repair of osteoporosis related fractures. We demonstrate that the site specific delivery of a 
bone-targeted gene knockdown system significantly improved new bone formation in osteoporosis related bone 
defects.
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